Showing 19 of 39 recruiting trials for “Tuberculosis”
Pragmatic Optimized Rifampicin Trial
RecruitingNCT06221488 ↗
Testing Health Workers At Risk to Advance Our Understanding of TB Infection
👨⚕️ Ruvandhi Nathavitharana, MBBS MPH, Beth Israel Deaconess Medical Center📍 1 site📅 Started Jan 2024View details ↗
Conventional Bronchoscope With BAL vs. Thin Bronchoscope With BW to Diagnose Pulmonary TB
RecruitingNCT06033807 ↗
Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients
TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts
Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above
👨⚕️ Shuihua Lu, bachelor, Shenzhen Third People's Hospital📍 8 sites📅 Started Aug 2023View details ↗
Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
👨⚕️ Catherine Ong, MRCP PhD, National University Hospital, Singapore📍 6 sites📅 Started May 2023View details ↗
Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)
👨⚕️ Wenhong Zhang, PhD., Huashan Hospital of Fudan University，Shanghai，China📍 6 sites📅 Started Jan 2023View details ↗
RecruitingNCT06522347 ↗
Mycobacteria Registry Study: Prospective Observational Study in Austria
BPaL(M) Regimen for the Treatment of MDR/RR-TB
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
👨⚕️ Mark Hatherill, University of Cape Town, Faculty of Health Sciences📍 1 site📅 Started Oct 2022View details ↗
My Mobile Wallet: An Intervention for Tuberculosis Medication Adherence in Rural Uganda
👨⚕️ Angella Musiimenta, PhD, Mbarara University of Science and Technology📍 1 site📅 Started Apr 2022View details ↗
The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot Study
RecruitingNCT06764576 ↗
Patients With Tuberculosis, Mycobacteriosis or Latent Tuberculosis
👨⚕️ Paola Dal Monte, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 1 site📅 Started Dec 2021View details ↗
RecruitingNCT05073926 ↗
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
RecruitingNCT04642755 ↗
Comorbidities and Coinfections in Latent TB
👨⚕️ Subash Babu, MBBS, PhD, National Institute for Research in Tuberculosis📍 1 site📅 Started Apr 2021View details ↗
Rapid Research in Diagnostics Development for TB Network
👨⚕️ Adithya Cattamanchi, MD, University of California, San Francisco📍 16 sites📅 Started Apr 2021View details ↗
Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
RecruitingNCT03691883 ↗
Design of an Integrative Algorithm for Staging Tuberculosis
👨⚕️ Cris Vilaplana, MD, PhD, Fundació Institut Germans Trias i Pujol📍 5 sites📅 Started Apr 2018View details ↗
← PreviousPage 2 of 2
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →